Cardiff Oncology

Cardiff Oncology is a clinical-stage biotechnology company focused on developing novel therapeutics for cancer treatment, with its lead drug candidate onvansertib targeting KRAS-mutated metastatic colorectal cancer and other tumor types. The company generates revenue primarily through partnerships, licensing agreements, and research grants as it advances its pipeline through clinical trials. Founded in 1999 and formerly known as Trovagene, Cardiff Oncology rebranded in 2020 to reflect its oncology focus and has since concentrated on precision medicine approaches. Its collaborations with major cancer centers and pharmaceutical companies are central to its strategy for advancing clinical development and commercialization. Understanding Cardiff Oncology’s emphasis on targeted therapies and its evolving partnerships is important for candidates interested in joining a dynamic, research-driven organization.

Recent Posts by Cardiff Oncology

1-5 of 5